BBIO catalysts
Catalysts and events linked to BBIO, newest first.
BBIO stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1 2026-10-12 · Up | commercial pipeline valuation and regulatory approval probability repricing | 91% normal PTH levels achieved in Phase 3 CALIBRATE study vs 0% on standard care. | Not recorded |
| BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for Encaleret 2026-10-12 · Up | pipeline commercialization derisking and cash flow revaluation | Positive Phase 3 CALIBRATE trial results for encaleret showing 91% PTH normalization. | Not recorded |
| BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret 2026-10-12 · Up | biotech clinical validation and regulatory progress | Positive Phase 3 CALIBRATE trial results and FDA regulatory filing acceptance announced. | Not recorded |
Do these developments change your position?
Review BBIO alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-12BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1BBIO-3.73%
- 2026-10-12BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1BBIO-3.73%
- 2026-10-12BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for EncaleretBBIO-3.73%
- 2026-10-12BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for EncaleretBBIO-3.73%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.